Literature DB >> 8537176

Peptidyl substrates containing unnatural amino acid at the P'1 position are potent inhibitors of prohormone convertases.

A Basak1, C Schmidt, A A Ismail, N G Seidah, M Chrétien, C Lazure.   

Abstract

In order to study further the importance of the P'1 residue upon the activity of human PC1 and human furin, two important members of subtilisin/kexin family of enzymes, we have prepared by solid-phase Fmoc or recently introduced FastMoc chemistry a series of 10 peptidyl substrate analogs. The structures of these analogs are based upon the core sequence of pro-mPC1(83-93) namely, D-Tyr-Lys-Glu-Arg-Ser-Lys-Arg-Xaa-Val-Gln-Lys-Asp, where D-Tyr replaces the native L-Tyr residue and Xaa, representing the P'1 position, corresponds to L-Ser or to nonproteinacous amino acids such as Tle, Sarc, MLeu, Aib, D-Tic or L-Tic. Two more analogs with L-Tic at P'1 position but with one amino acid less, namely P5 Glu or P'3 Gln, and one with a Cit residue in place of Arg at P1 site of the dodecapeptide were also obtained. These peptides were all fully characterized by a combination of MS, 1H-NMR and amino acid analysis. In contrast to the Ser analog, which is an excellent substrate for both hPC1 and hfurin, these analogs displayed moderate to strong inhibition of both hPC1 and hfurin activity in a reversible competitive manner. They all exhibited higher potency for hfurin than for hPC1, with an inhibition constant (Ki) ranging from 0.8 to 10 microM and from 1.0 to 170 microM, respectively. Incorporation of L-Tic yielded an analog with a two to four-fold increased inhibition of either enzymes when compared to its D-Tic counterpart, the effect being more pronounced for hPC1 than for hfurin. Comparison of these data with those for the corresponding N-terminal Fmoc protected peptides revealed that the highly hydrophobic N-terminal Fmoc function occupying the P8 position can contribute positively or negatively towards proteinase inhibition depending on the nature of the unnatural amino acid at P'1 and the enzyme used. Finally, none of the analogs was significantly cleaved by either enzyme. FTIR data on these analogs revealed some important structural differences between the substrate and inhibitor analogs, as there appears to be a conformational shift from a more beta-sheet-like structure for the substrates to a more alpha-helical-like structure for the inhibitors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537176     DOI: 10.1111/j.1399-3011.1995.tb00594.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  7 in total

1.  Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters.

Authors:  A Basak; S Cooper; A G Roberge; U K Banik; M Chrétien; N G Seidah
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

Review 2.  Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins.

Authors:  K Nakayama
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

Review 3.  Inhibitors of proprotein convertases.

Authors:  Ajoy Basak
Journal:  J Mol Med (Berl)       Date:  2005-10-08       Impact factor: 4.599

4.  Enzymic characterization in vitro of recombinant proprotein convertase PC4.

Authors:  A Basak; B B Touré; C Lazure; M Mbikay; M Chrétien; N G Seidah
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

5.  Synthetic peptides derived from the prosegments of proprotein convertase 1/3 and furin are potent inhibitors of both enzymes.

Authors:  Ajoy Basak; Claude Lazure
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

6.  Design of peptide inhibitors for furin based on the C-terminal fragment of histone H1.2.

Authors:  Suming Wang; Jinbo Han; Yanfang Wang; Wuyuan Lu; Chengwu Chi
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2008-10       Impact factor: 3.848

7.  A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C.

Authors:  Ajoy Basak; Abdel-Majid Khatib; Dayani Mohottalage; Sarmistha Basak; Maria Kolajova; Subhendu Sekhar Bag; Amit Basak
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.